Abstract:Expression of transcription factor estrogen receptor (ER) drives and defines almost three-fourth of all breast cancer (BC). Endocrine therapies such as tamoxifen and aromatase inhibitors form the backbone of therapeutic regimen in treatment of ER-positive (ER+) BC. However, some ER+ BC patients do not respond well to these therapies and develop endocrine resistance. Mechanisms of endocrine resistance is multi-faceted and may require inhibition of multiple pathways. FDA-approved inhibitors of CDK4/6 and mTOR pa… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.